Biotech Values

[RockRat]

TRIL: I see nothing new here. TRIL seems bottomed here in the low $4s. Just gotta be patient for one or two minor partnerships, and tidbits of very early data. I'd really like them to try and sell the more promising shelved Fluorinov programs, as they are wasting assets to some degree. They only mentioned the BET inhibitor in this regard, but they might be able to get token deals for a couple of the other ones. They don't have to get much to pay for their purchase.

Regards, RockRat